Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LB-4330 in Endometrial Carcinoma: NCT06468358 Clinical Landscape Report 2026
15 October 2026
NCT06468358 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY-4052031 in Metastatic Solid Tumor: NCT06465069 Clinical Landscape Report 2026
15 October 2026
NCT06465069 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bemcentinib in Acute Myeloid Leukemia: NCT06469138 Clinical Landscape Report 2026
15 October 2026
NCT06469138 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Izalontamab Brengitecan in Triple Negative Breast Cancer: NCT06471205 Clinical Landscape Report 2026
15 October 2026
NCT06471205 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Metastatic Renal Cell Carcinoma: NCT06472895 Clinical Landscape Report 2026
15 October 2026
NCT06472895 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PSMA(NeoTX) in Glioblastoma: CTRI/2024/06/069485 Clinical Landscape Report 2026
15 October 2026
CTRI/2024/06/069485 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma: NCT06477939 Clinical Landscape Report 2026
15 October 2026
NCT06477939 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Renal Cell Carcinoma: NCT06480565 Clinical Landscape Report 2026
15 October 2026
NCT06480565 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoposide in Large B-cell lymphoma: NCT06489808 Clinical Landscape Report 2026
15 October 2026
NCT06489808 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[212Pb] Bamzireotide Navoxetan in Olfactory Esthesioneuroblastoma: NCT06479811 Clinical Landscape Report 2026](https://synapse-static.patsnap.com/strapi-static/Blog_cover_B_112_156d4a2e9d.jpg)
9 min read
[212Pb] Bamzireotide Navoxetan in Olfactory Esthesioneuroblastoma: NCT06479811 Clinical Landscape Report 2026
15 October 2026
NCT06479811 clinical landscape for Olfactory Esthesioneuroblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RJK-002 in Amyotrophic Lateral Sclerosis: NCT06493279 Clinical Landscape Report 2026
15 October 2026
NCT06493279 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in PD-L1 positive Triple Negative Breast Cancer: NCT06492759 Clinical Landscape Report 2026
15 October 2026
NCT06492759 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…